Clinical Trial Update: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating B001 Injection for Neuromyelitis Optica Spectrum Disorders is currently recruiting. The sponsor listed is Shanghai Jiaolia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• B001 Injection

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 2, Phase 3 | Status: RECRUITING